“Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit?
Abstract “Platinum resistant” ovarian cancer was historically defined as disease recurrence
within 6 months of completion of first-line platinum-based chemotherapy, although this is …
within 6 months of completion of first-line platinum-based chemotherapy, although this is …
[PDF][PDF] The role of the fallopian tube in ovarian cancer
AA Tone, S Salvador, SJ Finlayson… - Clin Adv Hematol …, 2012 - researchgate.net
High-grade serous carcinoma (HGSC) is the most common and lethal subtype of ovarian
cancer. Research over the past decade has strongly suggested that “ovarian” HGSC arises …
cancer. Research over the past decade has strongly suggested that “ovarian” HGSC arises …
[HTML][HTML] Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
Background Niraparib is an oral poly (adenosine diphosphate [ADP]–ribose) polymerase
(PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We …
(PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We …
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
Purpose: The study aim to identify novel molecular subtypes of ovarian cancer by gene
expression profiling with linkage to clinical and pathologic features. Experimental Design …
expression profiling with linkage to clinical and pathologic features. Experimental Design …
[HTML][HTML] Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual …
Objective There is a need to develop and validate biomarkers for treatment response and
survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response …
survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response …
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Background Poly (ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian
carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 …
carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 …
Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient …
Importance Deficient mismatch mutation repair mechanisms may sensitize endometrial
cancers to anti–programmed death 1 (PD-1) therapies. Dostarlimab (TSR-042) is an …
cancers to anti–programmed death 1 (PD-1) therapies. Dostarlimab (TSR-042) is an …
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
W Sieh, M Köbel, TA Longacre, DD Bowtell… - The lancet …, 2013 - thelancet.com
Background Few biomarkers of ovarian cancer prognosis have been established, partly
because subtype-specific associations might be obscured in studies combining all …
because subtype-specific associations might be obscured in studies combining all …
[HTML][HTML] Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) …
A Oaknin, L Gilbert, AV Tinker, J Brown… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Dostarlimab is a humanized monoclonal antibody that binds with high affinity to
PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. We report interim data from …
PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. We report interim data from …
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200) …
E Pujade-Lauraine, K Fujiwara, JA Ledermann… - The lancet …, 2021 - thelancet.com
Background Most patients with ovarian cancer will relapse after receiving frontline platinum-
based chemotherapy and eventually develop platinum-resistant or platinum-refractory …
based chemotherapy and eventually develop platinum-resistant or platinum-refractory …